Press release -
Vironova AB signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).
In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body.
Proprietary Vironova Analyzing Software (VAS) in combination with Cryo-transmission electron microscopy (cryoTEM) enables semi-automated image analysis of liposomes, providing accurate, reproducible and timely results.
“Beta-testing is designed to help us accelerate development and improve the robustness and user friendliness of VAS. This is a very valuable compliment to the input from our internal microscopists who work with liposome characterization,” says Nina Ewerlöf, Head of Vironova instruments and software.
The U.S. Food and Drug Administration's National Center for Toxicological Research is a global resource for innovative scientific solutions in support of the agency’s mission to improve public health.
Topics
- Science, technology
Categories
- nanoparticles
- läkemedel
- vironova
- fda
- liposomes
Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova a company with 60 employees has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science. Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell- and virus facilities that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.
